Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
100%(1 trials)

Phase Distribution

Ph not_applicable
2
67%
Ph phase_1
1
33%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (33.3%)
N/A2 (66.7%)

Trials by Status

recruiting267%
completed133%

Recent Activity

2 active trials
Showing 3 of 3
recruitingphase_1

Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

NCT06650163
recruitingnot_applicable

Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis

NCT07339085
completednot_applicable

Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis

NCT04870645

Clinical Trials (3)

Showing 3 of 3 trials
NCT06650163Phase 1

Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

Recruiting
NCT07339085Not Applicable

Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis

Recruiting
NCT04870645Not Applicable

Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis

Completed

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3